GE expands Biosense Webster deal for ultrasound tech:
This article was originally published in Clinica
Executive Summary
GE Healthcare and Biosense Webster have extended a long-standing strategic partnership, with the aim of developing real-time ultrasound imaging technology for use in electrophysiology procedures. The partnership, of which financials details were not revealed, will see GE combine its ultrasound imaging capabilities with EP catheter technology belonging to Diamond Bar, California-based Biosense Webster. GE claims the two companies are to co-develop imaging solutions specifically for intracardiac therapies. The companies had previously built an alliance in order to integrate GE's CardioLab IT system for electrophysiology recording with Biosense Webster's Carto mapping system.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.